Neurotrope 10-Q 3 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 30, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	1,513,856
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		7,895,859

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 18,650,529	$ 25,773,533
Prepaid expenses	431,429	138,711
TOTAL CURRENT ASSETS	19,081,958	25,912,244
Fixed assets, net of accumulated depreciation	21,333	55,198
TOTAL ASSETS	19,103,291	25,967,442
CURRENT LIABILITIES
Accounts payable	1,617,686	2,167,413
Accrued expenses	50,027	190,744
Accrued expenses - related party	0	4,609
TOTAL CURRENT LIABILITIES	1,667,713	2,362,766
Commitments and contingencies
SHAREHOLDERS' EQUITY
Common stock - 150,000,000 shares authorized, $.0001 par value; 7,895,859 shares issued and outstanding at September 30, 2017; 6,754,547 shares issued and outstanding at December 31, 2016	790	676
Additional paid-in capital	75,783,955	73,648,737
Accumulated deficit	(58,349,167)	(50,044,737)
TOTAL SHAREHOLDERS' EQUITY	17,435,578	23,604,676
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 19,103,291	$ 25,967,442

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	7,895,859	6,754,547
Common stock, shares outstanding	7,895,859	6,754,547

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
OPERATING EXPENSES:
Research and development - related party	$ 75,431	$ 249,999	$ 164,619	$ 764,557
Research and development	744,618	1,729,929	3,662,589	3,548,608
General and administrative - related party	12,500	5,500	26,918	59,500
General and administrative	1,252,962	1,058,139	3,833,962	2,581,140
Stock-based compensation - related party	33,955	46,809	100,758	134,444
Stock-based compensation	197,146	503,283	581,664	830,335
TOTAL OPERATING EXPENSES	2,316,612	3,593,659	8,370,510	7,918,584
OTHER INCOME (EXPENSE):
Loss on abandonment of fixed assets	0	0	(34,274)	0
Gain on settlement of lease obligation	0	0	53,599	0
Interest income	20,298	1,516	46,755	5,450
Net loss before income taxes	(2,296,314)	(3,592,143)	(8,304,430)	(7,913,134)
Provision for income taxes	0	0	0	0
Net loss	(2,296,314)	(3,592,143)	(8,304,430)	(7,913,134)
Preferred Stock dividends	0	(512,397)	0	(1,537,149)
Net loss attributable to common shareholders	$ (2,296,314)	$ (4,104,540)	$ (8,304,430)	$ (9,450,283)
PER SHARE DATA:
Basic and diluted loss per common share (in dollars per share)	$ (0.29)	$ (2.64)	$ (1.08)	$ (6.13)
Basic and diluted weighted average common shares outstanding (in shares)	7,894,400	1,552,500	7,674,600	1,540,500

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Shareholders' Equity - 9 months ended Sep. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2016	$ 23,604,676	$ 676	$ 73,648,737	$ (50,044,737)
Balance (in shares) at Dec. 31, 2016		6,754,547
Issuance of common stock for consulting fees	121,645	$ 1	121,644	0
Issuance of common stock for consulting fees (in shares)		12,189
Exercise of common stock warrants	1,331,265	$ 113	1,331,152	0
Exercise of common stock warrants (in shares)		1,129,092
Stock based compensation	682,422	$ 0	682,422	0
Shares issued for reverse stock split rounding		31
Net loss	(8,304,430)	$ 0	0	(8,304,430)
Balance at Sep. 30, 2017	$ 17,435,578	$ 790	$ 75,783,955	$ (58,349,167)
Balance (in shares) at Sep. 30, 2017		7,895,859

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (8,304,430)	$ (7,913,134)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	682,422	964,779
Consulting services paid by issuance of common stock	121,645	0
Depreciation expense	3,176	5,187
Loss on abandonment of fixed assets	34,274	0
Change in assets and liabilities
(Increase) Decrease in prepaid expenses	(292,718)	1,280,503
(Increase) in prepaid expenses - related party	0	(14,358)
Decrease in subscription receivable	0	2,761
(Decrease) in accrued expenses - related party	(4,609)	(36,434)
(Decrease) increase in accounts payable	(549,727)	951,302
(Decrease) Increase in accrued expenses	(140,717)	57,708
Total adjustments	(146,254)	3,211,448
Net Cash Used in Operating Activities	(8,450,684)	(4,701,686)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(3,585)	(2,947)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of note payable	0	(10,511)
Proceeds from exercise of common stock warrants	1,331,265	274
Net Cash Provided by (Used in) Financing Activities	1,331,265	(10,237)
NET DECREASE IN CASH	(7,123,004)	(4,714,870)
CASH AT BEGINNING OF PERIOD	25,773,533	11,230,637
CASH AT END OF PERIOD	$ 18,650,529	$ 6,515,767
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Conversion of convertible redeemable preferred stock to common stock	0	244,179

Organization and Nature of Plan

Organization and Nature of Planned Business:	9 Months Ended
	Sep. 30, 2017
GENERAL ORGANIZATION AND BUSINESS [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Planned Business : Business Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 5). On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013, merged with and into Neurotrope BioScience (the “Reverse Merger”). Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock, par value $ 0.0001 The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date. As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.” Liquidity As of October 30, 2017, the Company had approximately $ 18 Basis of Presentation Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. However, the Company believes that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements included in this document have been prepared on the same basis as the annual consolidated financial statements, and in our opinion reflect all adjustments, which include normal recurring adjustments necessary for a fair presentation in accordance with GAAP and SEC regulations for interim financial statements. The results for the nine months ended September 30, 2017 are not necessarily indicative of the results that the Company will have for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2016 included in our Annual Report on Form 10-K.

Summary of Significant Accounti

Summary of Significant Accounting Policies:	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Summary of Significant Accounting Policies : The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2017, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation. Property and equipment is capitalized and depreciated on a straight line basis over the estimated useful life of the asset, which is deemed to be between three and ten years. As part of the settlement of obligations relating to its previous office lease, the Company wrote off approximately $ 34,274 All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2017 and December 31, 2016. Basic loss per common share amounts are based on weighted average number of common shares outstanding. Diluted loss per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options and warrants subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of September 30, 2017 and 2016, which were approximately 5.8 4.9 Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions for generally three years from the date of filing. Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company's ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. The Company has not completed a study to assess whether an ownership change for purposes of Section 382 has occurred, or whether there have been multiple ownership changes since the Company's inception, due to the significant costs and complexities associated with such study. The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option expense is recognized over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of Common Stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are revalued using the Black-Scholes option pricing model until the entire award vests. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non-public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception . Accounting Pronouncements Adopted During the Period: In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation

Contractual Commitments_

Contractual Commitments:	9 Months Ended
	Sep. 30, 2017
Contractual Commitments [Abstract]
Contractual Commitments [Text Block]	Note 3 – Contractual Commitments : On September 4, 2014, the Company entered into a lease for 4,000 136,100 82,500

Collaborative Agreements_

Collaborative Agreements:	9 Months Ended
	Sep. 30, 2017
Collaborative Agreements [Abstract]
Collaborative Agreements [Text Block]	Note 4 – Collaborative Agreements : Stanford License Agreements On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. On January 19, 2017, the Company entered into a second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $ 70,000 10,000 2.1 1.5 4.5 Mt. Sinai License Agreement On July 14, 2014, Neurotrope BioScience entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted Neurotrope BioScience a revenue-bearing, world-wide right and (a) exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (“PKCε”), which includes Niemann-Pick Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows Neurotrope BioScience to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (“Mount Sinai Licensed Product(s)”) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai Agreement). During the nine months ended September 30, 2017, the Company paid Mount Sinai $ 10,000 Clinical Trial Services Agreement On October 9, 2015, Neurotrope BioScience executed a Services Agreement (the “Services Agreement”) with Worldwide Clinical Trials (“WCT”), effective as of August 31, 2015. The Agreement relates to services for Neurotrope BioScience’s Phase 2 clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe AD (the “Study”). Pursuant to the terms of the Services Agreement, WCT provided services to enroll approximately one hundred and fifty (150) Study subjects. The first Study site was initiated during the fourth quarter of 2015. The total estimated budget for the services, including pass-through costs, is approximately $ 9.5 200,000 On November 11, 2015, Neurotrope BioScience paid WCT approximately $3.1 million. The remaining payments of approximately $ 6.4 Also, in connection with the execution of the Services Agreement, Neurotrope BioScience received consent and entered into a Statement of Work pursuant to its CRE License Agreement (see Note 5 below). CRE License Agreement On July 27, 2016, the Company received approval of the institutional review board (“IRB”) for its amended protocol submitted on July 21, 2016 to the U.S. Food and Drug Administration (the “FDA”) relating to the Phase 2 clinical trial of the Company’s lead drug candidate, bryostatin-1, for the treatment of advanced AD, which amended protocol eliminates the second, exploratory, study period following the first 12 weeks of treatment. The primary objective was the assessment of safety and tolerability of bryostatin to occur at 13 weeks, which was not changed with this amendment. The secondary objective was to assess efficacy, also at week 13. The amendment to cut the exploratory part of the study was made for business reasons in order to provide earlier completion of the study and for the planning of future studies. The changes to the study design were not due to any safety concerns. The cost savings from this amendment was approximately $ 2

Related Party Transactions and

Related Party Transactions and Licensing / Research Agreements:	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5 – Related Party Transactions and Licensing / Research Agreements : As of September 30, 2017, James Gottlieb, a director of the Company, served as a director of CRE, and Shana Phares, also a director of the Company, served as President and Chief Executive Officer of CRE. CRE is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 3.6 Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement (the “TLSA”) with CRE, a related party, and NRV II, LLC (“NRV II”), another affiliate of CRE, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “CRE License Agreement”). The CRE License Agreement provides research services and has granted Neurotrope BioScience the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the TLSA specifies that all patents that issue from a certain patent application, shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain. After the initial Series A Stock financing, the CRE License Agreement required Neurotrope BioScience to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. In addition, the CRE License Agreement requires the Company to pay CRE a “Fixed Research Fee” of $ 1 25,000,000 2 5 5 On November 12, 2015, Neurotrope BioScience, CRE, and NRV II entered into an amendment (the “Amendment”) to the TLSA pursuant to which CRE granted rights in certain technology to Neurotrope BioScience. Under the Amendment, the “Advances on Future Royalties” section of the TLSA was amended and restated to (i) eliminate the requirement that Neurotrope BioScience pay CRE prepaid royalties equal to five percent ( 5 2.5

Common Stock_

Common Stock:	9 Months Ended
	Sep. 30, 2017
STOCKHOLDERS' EQUITY [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 6 – Common Stock: During the nine months ended September 30, 2017, 108 holders of 1,051,371 0.32 1,051,371 77,721 12.80 77,721 During the three months ended September 30, 2017, no warrant holders exercised warrants into Common Stock. On August 1, 2017, the Company issued 4,063 4.21 Reverse Stock Split On January 11, 2017, the Company effected a 1-for-32 400,000,000 12,500,000 On February 17, 2017, the stockholders of the Company approved as increase in the number of authorized shares of Common Stock to 150

Stock Options_

Stock Options:	9 Months Ended
	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock Option Note Disclosure [Text Block]	Note 7 – Stock Options : The Board adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to 218,750 On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by 93,750 312,500 Effective on November 21, 2016, the Company amended the 2013 Plan pursuant to an Amendment to the Neurotrope, Inc. 2013 Equity Incentive Plan (the “Equity Incentive Plan Amendment”) to increase the number of shares of Common Stock available for issuance under the Plan to 685,325 On March 9, 2017, the Company’s Board of Directors approved the Neurotrope, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which provides for the issuance of incentive awards of up to 800,000 70,000 248,445 Option Grants Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in millions) Options outstanding at January 1, 2017 675,812 $ 23.54 8.3 $ - Options granted 9,375 $ 15.77 Less options forfeited (1,952) $ 19.20 Less options expired/cancelled - $ - Less options exercised - $ - Options outstanding at September 30, 2017 683,235 $ 23.45 8.3 $ - Options exercisable at September 30, 2017 481,225 $ 27.43 8.0 $ - During the nine months ended September 30, 2017, the Company issued 9,375 15.77 70,000 As of September 30, 2017, there was approximately $ 2.2 3.1 The Company used the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of stock options issued for the nine months ended September 30, 2017 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0 89.31 2.420 13.57 The total stock option-based compensation recorded as operating expense was $ 682,422 964,779 231,101 550,092

Common Stock Warrants_

Common Stock Warrants:	9 Months Ended
	Sep. 30, 2017
Stock Option Note Disclosure [Text Block]	Note 7 – Stock Options : The Board adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to 218,750 On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by 93,750 312,500 Effective on November 21, 2016, the Company amended the 2013 Plan pursuant to an Amendment to the Neurotrope, Inc. 2013 Equity Incentive Plan (the “Equity Incentive Plan Amendment”) to increase the number of shares of Common Stock available for issuance under the Plan to 685,325 On March 9, 2017, the Company’s Board of Directors approved the Neurotrope, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which provides for the issuance of incentive awards of up to 800,000 70,000 248,445 Option Grants Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in millions) Options outstanding at January 1, 2017 675,812 $ 23.54 8.3 $ - Options granted 9,375 $ 15.77 Less options forfeited (1,952) $ 19.20 Less options expired/cancelled - $ - Less options exercised - $ - Options outstanding at September 30, 2017 683,235 $ 23.45 8.3 $ - Options exercisable at September 30, 2017 481,225 $ 27.43 8.0 $ - During the nine months ended September 30, 2017, the Company issued 9,375 15.77 70,000 As of September 30, 2017, there was approximately $ 2.2 3.1 The Company used the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of stock options issued for the nine months ended September 30, 2017 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0 89.31 2.420 13.57 The total stock option-based compensation recorded as operating expense was $ 682,422 964,779 231,101 550,092
Warrant [Member]
Stock Option Note Disclosure [Text Block]	Note 8 – Common Stock Warrants : Number of shares Warrants outstanding January 1, 2017 6,244,366 Warrants exercised (1,129,092) Warrants outstanding September 30, 2017 5,115,274 As of September 30, 2017, the Company’s warrants by exercise price were as follows: 161,440 0.32 382,887 6.40 3,751,033 12.80 819,914 32.00

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 9 – Contingencies Since May 17, 2017, two purported class action lawsuits have been commenced in the United States District Court for the Southern District of New York (the “NY Litigation”). On August 10, 2017, the lawsuits were consolidated and Plaintiff filed its Amended Consolidated Complaint on October 9, 2017. The Amended Consolidated Complaint names as defendants the Company, its Chief Executive Officer and its co-founder and President/Chief Scientific Officer. The lawsuit alleges violations of the Securities Exchange Act of 1934, as amended, in connection with allegedly false and misleading statements made by the Company in certain press releases and in its Annual Report on Form 10-K relating to the results stemming from the Company’s Phase 2b clinical trial for bryostatin. Plaintiffs seek, among other things, damages for purchasers of the Company’s securities between January 7, 2016 and July 18, 2017. Because each of the pending actions is in the early stages, no reasonable estimate of possible loss, if any, can be made. The Company and its directors and officers believe that this action is without merit and intend to defend the lawsuit vigorously. The Company and other named defendants intend to the move the dismiss all of the claims. The Court has set a November 21, 2017 deadline for the motions to dismiss and the motions should be fully briefed by early January 2018. Additionally, on August 3, 2017 a derivative action was filed against the Company and all current members of the Board of Directors. The lawsuit alleges that the Board of Directors breached its fiduciary duty by making misleading statements and omitting information pertaining to the results of the Company’s Phase 2b clinical trials for bryostatin. The Company and the Board of Directors have reached an agreement in principal with counsel for the Plaintiff to stay this action pending a decision by the Court in the NY Litigation. The Company filed a stipulation with the Court memorializing the agreement with Plaintiff’s counsel in October 2017.

Summary of Significant Accoun16

Summary of Significant Accounting Policies: (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2017, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment: Property and equipment is capitalized and depreciated on a straight line basis over the estimated useful life of the asset, which is deemed to be between three and ten years. As part of the settlement of obligations relating to its previous office lease, the Company wrote off approximately $ 34,274
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2017 and December 31, 2016.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share: Basic loss per common share amounts are based on weighted average number of common shares outstanding. Diluted loss per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options and warrants subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of September 30, 2017 and 2016, which were approximately 5.8 4.9
Income Tax, Policy [Policy Text Block]	Income Taxes: Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions for generally three years from the date of filing. Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company's ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. The Company has not completed a study to assess whether an ownership change for purposes of Section 382 has occurred, or whether there have been multiple ownership changes since the Company's inception, due to the significant costs and complexities associated with such study.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Risks and Uncertainties: The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Compensation: The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option expense is recognized over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of Common Stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are revalued using the Black-Scholes option pricing model until the entire award vests.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements: In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non-public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception . Accounting Pronouncements Adopted During the Period: In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation

Stock Options_ (Tables)

Stock Options: (Tables)	9 Months Ended
	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2017: Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in millions) Options outstanding at January 1, 2017 675,812 $ 23.54 8.3 $ - Options granted 9,375 $ 15.77 Less options forfeited (1,952) $ 19.20 Less options expired/cancelled - $ - Less options exercised - $ - Options outstanding at September 30, 2017 683,235 $ 23.45 8.3 $ - Options exercisable at September 30, 2017 481,225 $ 27.43 8.0 $ -

Common Stock Warrants_ (Tables)

Common Stock Warrants: (Tables)	9 Months Ended
	Sep. 30, 2017
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2017: Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in millions) Options outstanding at January 1, 2017 675,812 $ 23.54 8.3 $ - Options granted 9,375 $ 15.77 Less options forfeited (1,952) $ 19.20 Less options expired/cancelled - $ - Less options exercised - $ - Options outstanding at September 30, 2017 683,235 $ 23.45 8.3 $ - Options exercisable at September 30, 2017 481,225 $ 27.43 8.0 $ -
Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of common stock warrant activity for the nine months ended September 30, 2017: Number of shares Warrants outstanding January 1, 2017 6,244,366 Warrants exercised (1,129,092) Warrants outstanding September 30, 2017 5,115,274

Organization and Nature of Pl19

Organization and Nature of Planned Business: (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Oct. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Subsequent Event [Member]
Cash, Cash Equivalents, and Short-term Investments	$ 18

Summary of Significant Accoun20

Summary of Significant Accounting Policies: (Details Textual) - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			5.8	4.9
Gain (Loss) on Disposition of Assets	$ 0	$ 0	$ (34,274)	$ 0
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life			10 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life				3 years

Contractual Commitments_ (Detai

Contractual Commitments: (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 23, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	May 01, 2016USD ($)	Sep. 04, 2014ft²
Contractual Commitments And Contingencies [Line Items]
Area of Land | ft²							4,000
Description of Lessor Leasing Arrangements, Operating Leases				The lease commenced on September 1, 2014 and was to expire on December 1, 2017 and had two (2) one-year renewal options.
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year						$ 136,100
Payment For Lease Settlement	$ 82,500
Gain (Loss) on Contract Termination		$ 0	$ 0	$ 53,599	$ 0

Collaborative Agreements_ (Deta

Collaborative Agreements: (Details Textual) - USD ($)	Oct. 09, 2015	Jan. 19, 2017	Sep. 30, 2017	Jul. 27, 2016	Nov. 11, 2015
Collaborative Agreements [Line Items]
Annual License Maintenance Fee		$ 10,000
Commitment To Pay Fees		2,100,000
Estimated Budget For Services				$ 9,500,000
Payments for Advance to Affiliate	$ 200,000
Clinical Trial, Amended Protocol, Cost savings			$ 2,000,000
License Costs		$ 70,000
Minimum [Member]
Collaborative Agreements [Line Items]
Royalty Payment Percentage		1.50%
Maximum [Member]
Collaborative Agreements [Line Items]
Royalty Payment Percentage		4.50%
July 2016 Through September 2017 [Member]
Collaborative Agreements [Line Items]
Estimated Budget For Services					$ 6,400,000
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee			$ 10,000

Related Party Transactions an23

Related Party Transactions and Licensing / Research Agreements: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 12, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Related Party Transaction [Line Items]
Research and Development Expense, Total		$ 744,618	$ 1,729,929	$ 3,662,589	$ 3,548,608
Payments for Royalties				1,166,666
Blanchette Rockefeller Neurosciences Institute [Member]
Related Party Transaction [Line Items]
Royalties Percentage	5.00%
Post PA Fee Proceeds Percent	2.50%
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total				$ 1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage				5.00%
Services Reimbursement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage				2.00%
Services Reimbursement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage				5.00%
Series B Preferred Stock [Member] | Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 25,000,000
President [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		3.60%		3.60%

Common Stock_ (Details Textual)

Common Stock: (Details Textual) - $ / shares	Jan. 11, 2017	Aug. 01, 2017	Sep. 30, 2017	Feb. 17, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Common Stock, Shares Authorized	12,500,000		150,000,000	150,000,000	150,000,000
Stock Issued During Period, Shares, Issued for Services		4,063
Shares Issued, Price Per Share		$ 4.21
Stockholders' Equity, Reverse Stock Split	1-for-32
Exercise Price 12.80 [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 12.80
Exercise Price 0.32 [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.32
Scenario, Previously Reported [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized	400,000,000
108 holders [Member] | Exercise Price 12.80 [Member]
Class of Stock [Line Items]
Warrants Exercisable			77,721
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			77,721
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 12.80
108 holders [Member] | Exercise Price 0.32 [Member]
Class of Stock [Line Items]
Warrants Exercisable			1,051,371
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,051,371
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.32

Stock Options_ (Details)

Stock Options: (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	675,812
Number of Shares, Options granted	9,375
Number of Shares, Less options forfeited	(1,952)
Number of Shares, Less options expired/cancelled	0
Number of Shares, Less options exercised	0
Number of Shares, Outstanding	683,235	675,812
Number of Shares, Options exercisable	481,225
Weighted-Average Exercise Price, Outstanding	$ 23.54
Weighted-Average Exercise Price, Options granted	15.77
Weighted - Average Exercise Price, options forfeited	19.2
Weighted-Average Exercise Price, options expired/cancelled	0
Weighted-Average Exercise Price, Options exercised	0
Weighted-Average Exercise Price, Outstanding	23.45	$ 23.54
Weighted-Average Exercise Price, Options exercisable	$ 27.43
Weighted-Average Remaining Contractual Term, Outstanding (in years)	8 years 3 months 18 days	8 years 3 months 18 days
Weighted-Average Remaining Contractual Term, exercisable (in years)	8 years
Aggregate Intrinsic Value, Outstanding	$ 0	$ 0
Aggregate Intrinsic Value, exercisable	$ 0

Stock Options_ (Details Textual

Stock Options: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 23, 2014	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Apr. 11, 2017	Mar. 17, 2017	Mar. 09, 2017	Nov. 21, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				89.31%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.42%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 13.57
Employee Benefits and Share-based Compensation		$ 231,101	$ 550,092	$ 682,422	$ 964,779
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 2,200,000		$ 2,200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				3 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				9,375
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 15.77
Two Thousand Seventeen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								800,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		70,000		70,000
Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						248,445	70,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		218,750		218,750
Equity Incentive Plan 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	312,500
Equity Incentive Plan 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	93,750
Equity Incentive Plan Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									685,325

Common Stock _Warrants_ (Detail

Common Stock  Warrants: (Details)	9 Months Ended
	Sep. 30, 2017shares
Warrants outstanding January 1, 2017	6,244,366
Warrants exercised	(1,129,092)
Warrants outstanding September 30, 2017	5,115,274

Common Stock Warrants_ (Details

Common Stock Warrants: (Details Textual)	Sep. 30, 2017$ / sharesshares
Exercise Price 0.32 [Member]
Class of Warrant or Right, Outstanding | shares	161,440
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.32
Exercise Price 12.80 [Member]
Class of Warrant or Right, Outstanding | shares	3,751,033
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 12.80
Exercise Price 6.40 [Member]
Class of Warrant or Right, Outstanding | shares	382,887
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 6.40
Exercise Price 32.00 [Member]
Class of Warrant or Right, Outstanding | shares	819,914
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 32